-0.04 | -0.10%
| Price and Volume | |
|---|---|
| Recent Price | 39.87 |
| 52 Week High | 44.95 |
| 52 Week Low | 28.82 |
| Avg. Daily Vol. (Mil) | 0.69 |
| Beta (3 year) | 0.45 |
| Share Related Items | |
| Mkt Cap (Mil) | 2,525.26 |
| Shares Out (Mil) | 63.34 |
| Float (Mil) | 54.48 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.40 |
| Current Ratio | 5.90 |
| LT Debt/ Equity | 0.54 |
| Total Debt / Equity | 0.54 |
| Valuation Ratios | |
| Price Earnings | 72.50 |
| Price/Sales | 3.14 |
| Price/Book | 2.95 |
| Price/Cash Flow | 28.70 |
| Per Share Data | |
| Earnings | 0.55 |
| Sales | 12.68 |
| Book Value | 13.50 |
| Cash Flow | 1.39 |
| Business Summary | |
|---|---|
| Cubist Pharmaceuticals, Inc is focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. | |
| General Information | |
| 65 Hayden Avenue
Lexington, MA 02421 |
|
| www.cubist.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 669 | |
| CEO: Michael W. Bonney | |
| Short Interest | |
| Current Month (Mil) | 10.42 |
| Previous Month (Mil) | 10.67 |
| Short Interest Ratio (Days) | 12.70 |
| Management Effectiveness | |
| Return on Equity | 5.10 |
| Return on Assets | 2.30 |
| Return on Investments | 3.30 |
| Profitability | |
| Gross Margin | 81.90 |
| EBIT Margin | 18.80 |
| Profit Margin | 5.40 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet